Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain - Sanchez-Luna, M; Burgos-Pol, R; Oyagüez, I (BMC Infect Dis, 2017)
, et al.